TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from BioCryst ( (BCRX) ) is now available.
On December 3, 2025, BioCryst Pharmaceuticals announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics. This development satisfies one of the conditions for the merger, which is expected to close in the first quarter of 2026, pending other customary closing conditions. The merger is anticipated to enhance BioCryst’s market position, although it carries risks such as potential integration challenges and financial implications.
The most recent analyst rating on (BCRX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s overall stock score is primarily influenced by its financial performance challenges, including high leverage and cash flow issues. While the earnings call provided positive insights into revenue growth and strategic initiatives, the technical analysis and valuation metrics indicate bearish sentiment and limited immediate return potential.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases. The company has commercialized ORLADEYO®, the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases.
Average Trading Volume: 4,759,543
Technical Sentiment Signal: Sell
Current Market Cap: $1.5B
Find detailed analytics on BCRX stock on TipRanks’ Stock Analysis page.